For Immediate ReleaseChicago, IL – September 27, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Home Depot, Inc. HD, salesforce.com, inc. CRM, Pfizer Inc. PFE, Sony Group Corporation SONY and Zoetis Inc. ZTS.Here are highlights from Friday’s Analyst Blog:Top Research Reports for Home Depot, salesforce and PfizerThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, salesforce.com, and Pfizer. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Shares of Home Depot have modestly outperformed the Zacks Retail Building Products industry over the past year (+28.5% vs. +25.8%). The Zacks analyst acknowledges the fact that the One Home Depot plan, which focuses on expanding supply chain, technology investments and digital enhancements has proved to be greatly beneficial for the company.Steady growth in Pro and DIY customer categories is another major catalyst for growth. It has also been effectively adapting to the demand for renovations and construction activities, driven by prudent investments. Increased penetration of lumber products and continued pressure from higher transportation costs are major concerns though. The company also witnessed year-over-year moderation in its comparable store sales growth in second-quarter fiscal 2021.(You can read the full research report on Home Depot here >>>)salesforce shares have gained +37% in the last six months against the Zacks Computer Software industry's gain of +29.4%. The Zacks analyst believes that diverse cloud offerings, clientele strength, strategic acquisitions and partnerships have been driving the company's growth.salesforce's sustained focus on introducing more aligned products and continued deal wins in the international market have been boosting its top line. Slack's acquisition is also likely to position the company as a leader in the enterprise team collaboration solution space. Cut-throat competition, currency fluctuations and increased spending on international expansions and data centers have been weighing on the company's near-term prospects though.(You can read the full research report on salesforce here >>>)Shares of Pfizer have gained +14.3% in the past three months against the Zacks Large-Cap Pharmaceuticals industry's gain of +1.9%. The Zacks analyst believes that its sustainable pipeline with multiple late-stage programs is likely to drive growth.Its COVID-19 vaccine candidate has now been approved for emergency use in several countries, thereby becoming a key contributor to the top line. The Consumer Healthcare JV with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Currency headwinds and pricing pressure, however, remain as major headwinds.(You can read the full research report on Pfizer here >>>)Other noteworthy reports we are featuring today include Sony Group Corp. and Zoetis.Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report salesforce.com, inc. (CRM): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report The Home Depot, Inc. (HD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report Sony Corporation (SONY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research